Definitive Contract HHSN272201400051C
Award Date 9/23/14
Potential Completion Date 9/20/22
Potential Value $13M
Federal Agency
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
La Jolla, CA 92093, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
16
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The University of California, San Diego (UCSD) was awarded a $10,223,791 Definitive Federal Contract by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. This contract does not have a set-aside designation. As part of this effort, UCSD has issued subcontracts to several companies, including Life Technologies Corporation, Inimmune Corp,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $10.3 million definitive cost-no-fee contract to the University of California, San Diego on September 30, 2024, to support the Vaccine Adjuvant Discovery Program (VADP). This five-year effort, which extends through September 2029, is being performed in La Jolla, California. The contract represents a bilateral modification to descope activities for fiscal year 2025 cost savings. No set-aside designation was used in this...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the University of California San Diego (UCSD) for the "Development of Small-Molecule Dual Adjuvant System for Influenza Virus Vaccine". The $6,359,752.05 firm fixed-price contract has a completion date of September 29, 2028. This contract is not set aside and was awarded directly to UCSD. UCSD is a renowned public research university and the parent...
- This is a $8,012,241.00 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to the University of California San Diego. The contract is for biomedical research and analysis services and does not have a set-aside designation. University of California San Diego has previously provided similar medical laboratory testing, brain analysis, and other services to the Department of Veterans Affairs...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $10.2M cost-reimbursable contract to the University of California, Irvine (UCI) on September 1, 2022, for adjuvant comparison and characterization research. Under this definitive contract with a completion date of January 1, 2027, UCI will conduct comprehensive immune assessments comparing multiple adjuvants across various vaccine and antigen platforms. The work, to be performed in Irvine, California, supports NIAID's...
- The Department of Health and Human Services' National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9,896,692 Vaccine Adjuvant Discovery Program (VADP) contract to the University of Montana. The 5-year contract, which has no set-aside designation, aims to identify, characterize, and advance novel synthetic adjuvants for use in combination with bacterial and fungal antigens to induce a safe and durable T-helper 17 (Th17) and/or Th17/Th1 immune response. The University of Montana...
- This definitive federal contract was awarded by the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases to the La Jolla Institute for Immunology, a non-profit research organization, to conduct large-scale T cell epitope discovery research. The contract has a potential value of $4,499,760.00 and is not set aside for any specific business type. The contract involves multiple subcontractors to assist with the research, including the Universidad Peruana...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9.5M definitive contract to the University of Chicago on September 30, 2024, under the Vaccine Adjuvant Discovery Program (VADP). This cost-no-fee contract, which extends through September 29, 2029, supports research conducted at the university's Chicago, Illinois campus. The award represents a bilateral modification to descope the program for FY2025 cost savings, as indicated by the contract's stated objective of...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to The Leland Stanford Junior University (Stanford University), a private research institution. The $19,155,153 contract is for a 5-year research program to compare multiple vaccine adjuvants and comprehensively assess the immune responses they induce. The goal is to develop "immune fingerprints" of adjuvants using advanced...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the La Jolla Institute for Immunology (LJII), a non-profit research institute. The contract, valued at $52,963,056.00, is for the "IMMUNE EPITOPE DATABASE AND ANALYSIS PROGRAM" and does not have a set-aside designation. The contract is a definitive contract with a cost-no-fee pricing type, with a period of performance ending on...